Build · Recursion
Recursion and Bayer collaborate on up to seven precision oncology programs.
The partnership targets high-unmet-need oncology indications. The partners page lists $80M upfront plus equity investment and up to $1.5B in success-based payments plus royalties.
Recursion is a US techbio company running Recursion OS and large biological maps for drug discovery with pharma partners including Roche, Genentech, Sanofi and Bayer.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Source
Published by Recursion on its own site — read the original case study on recursion.com ↗
Note: Partners overview page, not a dedicated case study.
More like this
Related use cases
- 01Recursion and Roche/Genentech run a multi-year collaboration using Recursion OS and Maps of Biology in neuroscience and oncology.
- 02Recursion and Sanofi collaborate to discover and advance up to 15 novel targets in oncology and immunology.
- 03OpenAI's dedicated healthcare vertical page/launch post.
- 04Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 05follow-up update to the life-sciences model.
- 06"How Amgen uses GPT-5": Amgen applies GPT-5/frontier models to help accelerate delivery of potential new therapies; found GPT-5 met scientific-accuracy standards.